



Research Article

Histological and Histochemical Alternations in the Fetal Heart Tissue of Maternal Prozac Exposure

¹Mervat Ahmed Abd Rabou and ²Khadija Abdul Jalil Faddladdeen

¹Biology Department, College of Science, Jouf University, P.O. Box 2014, Sakaka, Saudi Arabia

²Faculty of Science, King Abdul Aziz University, Saudi Arabia

Abstract

Background and Objective: Depression during gestation destructively affects fetal development. Fluoxetine (Prozac) as a selective serotonin reuptake inhibitor (SSRIs) is used for handling of maternal despair. Anti-depressants cross the placenta and are transported to the fetus. This study aimed to determine the effects of fluoxetine on histopathological and histochemical changes in fetal heart tissue maternally treated with Fluoxetine. **Materials and Methods:** Forty pregnant rats were categorized into the following groups: Control group, group of 10 pregnant rats treated daily with 0.72 mg kg⁻¹ b.wt. Fluoxetine (treatment started one month before pregnancy and continued till end of gestation), group of 10 pregnant rats treated daily with 1.44 mg kg⁻¹ b.wt. Fluoxetine (treatment started from day zero till day 20 of pregnancy), group of 10 pregnant rats treated daily with 2.88 mg kg⁻¹ b.wt. Fluoxetine (treatment started from day zero till day 20 of pregnancy). Pregnant mothers were sacrificed on day 19 of gestation and small samples of fetal heart were taken for the histological and histochemical studies. **Results:** Many histological and histochemical alternations were observed in fetal heart of all the treated groups compared with control group. The harshness of these changes increased with increasing the doses of Fluoxetine. **Conclusion:** Maternal fluoxetine exposure caused harmful changes in the fetal heart, therefore the use of this drug during gestation should be under strict precautions and further studies are recommended that it is essential to survey the roles of anti-depressant drugs on fetal development during pregnancy.

Key words: Prozac (fluoxetine), selective serotonin reuptake inhibitor, pregnant rats, fetal heart tissue, antidepressant drugs

Received:

Accepted:

Published:

Citation: Mervat Ahmed Abd Rabou and Khadija Abdul jalil Faddladdeen, 2019. Histological and histochemical alternations in the fetal heart tissue of maternal Prozac exposure. Int. J. Pharmacol., CC: CC-CC.

Corresponding Author: Mervat Ahmed Abd Rabou, Biology Department, College of Science, Jouf University, P.O. Box 2014, Sakaka, Saudi Arabia
Tel: 00966537242262

Copyright: © 2019 Mervat Ahmed Abd Rabou and Khadija Abdul jalil Faddladdeen. This is an open access article distributed under the terms of the creative commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Competing Interest: The authors have declared that no competing interest exists.

Data Availability: All relevant data are within the paper and its supporting information files.

INTRODUCTION

The gestational period is a physiologic marvel. It is described by many changes as, physical, hormonal, mental and social changes that can specifically impact a females' mental health. The rise of gravidity hormones level, estrogen and progesterone, can bring about mental issue, which can be less or more viable trusting upon the affectability of every female¹.

During gestation there is a high exposure to medicines. The exposure to medicines during pregnancy have a potential hazard of teratogenic effects^{2,3}. Pregnant women often need psychiatric handling in face of emotional illnesses caused by pressure and anxiety⁴. The emotional state during gestation is an important reason in medicine. Pregnancy increases the vulnerability for depression onset or return⁵. Mood disorders are public with prevalence rates for depression reported to be 7.4% in the first trimester, 12.8% in the second trimester and 12.0% in the third trimester⁶.

Depression during antenatal period are associated with major effects outcomes for mother, developing fetus and the neonate^{7,8}.

Selective Serotonin Reuptake Inhibitors (SSRIs) have been studied for antepartum despair based on the severity of state⁹. The SSRI therapy has been aimed to have a relation with neurobehavioral disturbances, preterm birth, lower birth weight, neurotoxic effects and behavior teratogenic effects, cardiac defects, pulmonary hypertension, movement disorders and seizure¹⁰. Recent studies reported the use of fluoxetine, tricyclic anti-depressants and serotonin reuptake inhibitors in pregnant women^{11,12}.

Prozac during organogenesis, drug can be considered as a teratogenic influence, thereby causing congenital defects and serious injuries that may lead to abortion¹³.

Fluoxetine fits to the pharmacological group of the serotonin reuptake selective inhibitors. Because it does not fix to histamine, acetylcholine and epinephrine receptors, it has less analgesic, anti-cholinergic and cardiovascular properties than the tricyclic anti-depressants¹⁴. Increase in serotonin levels, thus leading to a passing reduction in uterine blood stream. This drops the oxygen and nutrient supply to the fetus, reduces its growth and leads it to premature birth. Also, it affects the fetus neural development¹². Fluoxetine was carefully chosen for being the anti-depressant of choice for pregnant women and most studies have focused on fluoxetine because of its high selectivity and negligible affinity for numerous receptor subtypes.

The administration of Fluoxetine to pregnant rats led to variable histopathological alternations on different fetal organs such as lung, heart and kidney¹⁵. Many histological and histochemical changes were detected in fetal skin maternal exposure to Prozac².

Histopathological studies of fetuses during gestational period discovered degeneration of hepatocytes, vacuolization and necrotic areas within the cytoplasm. Swelling of glomeruli and degeneration of cells lining renal tubules were detected in the fetal kidney and degenerative changes were observed in the brain following trazodone administration from anti-depressant of the serotonin antagonist reuptake inhibitor¹.

Some studies have demonstrated that maternal exposure to fluoxetine in early pregnancy was associated with cardiac malformation and congenital heart defects¹⁶, while some studies have shown that there is no linkage between SSRIs and congenital heart defects¹⁷. Studies have also shown that fluoxetine can lead to ventricular septal defects¹⁸ and atrial septal defects¹⁹.

Placental transfer of antidepressant medications to the fetus and this cause damage the organs of fetuses and the heart tissue of fetuses more sensitive to drugs, so the present study was aimed to evaluate the possible histopathological and histochemical alternations in the heart of fetuses maternally exposed to fluoxetine with three different doses (0.72 and 1.44 and 2.88 mg kg⁻¹ b.wt.).

MATERIALS AND METHODS

Experimental animals: A total of 40 female *Albino rattus norvegicus* and 20 male, weight 200-280 g b.wt., were selected. Rats fed on standard diet and some vegetables. Before the research, all rats were waited for 2 weeks in metal cages under standard laboratory environments of light (12 h light /dark cycle), temperature 25 ± 5 in July and August, 2016 and approval for this study was obtained from the ethics committee of Al-Azhar University, Faculty of Science, Egypt.

Induction of pregnancy: Estrous cycle was firm according to Taylor²⁰. Vaginal smears were collected daily for estrous cycle purpose and then the estrous rats were placed with healthy male in the ratio of 2:1 for coupling. In the following morning, mating was confirmed by presence of sperms in the vaginal slight or presence of the vaginal mass that was considered as day zero of gestation²¹. The pregnant rats were categorized and separated, after one week of coupling, non-pregnant rats were barred.

Experimental groups: Forty pregnant rats were used and categorized into four groups after mating, each group was contained 10 rats: group 1 (Control group C), group 2 (pregnant rats were treated daily with 0.72 mg kg⁻¹ b.wt., Prozac (T1) treatment started one month before pregnancy and continued till day 19 of gestation, group 3: Pregnant rats were treated daily of gestation with 1.44 mg kg⁻¹ b.wt., Prozac (T2), group 4: Pregnant rats were treated daily of gestation with 2.88 mg kg⁻¹ b.wt., Prozac (T3). Prozac doses were determined after alteration from human doses according to Paget and Barnes²².

Histological and histochemical study: Pregnant rats from all the treated and control groups were sacrificed on day 19 of pregnancy and small samples of heart were taken for the histological and histochemical studies. These pieces were fixed in 10% neutral buffered formalin solution and Carnoy's fluid for the histological and histochemical studies. Paraffin sections were prepared 5 µm thicknesses and marked with

Harris haematoxylin and eosin²³. Mallory's trichrome stain²⁴ for staining collagen fibers. Polysaccharides were detected by PAS (periodic acid Schiff) method²⁵. Total proteins were spotted by mercuric bromophenol blue technique²⁶. The DNA content were perceived by Feulgen method²⁴.

Image analysis: The optical transparency (pexil) of the PAS positive materials, total protein and DNA content were recorded. The analysis of differences between groups were performed with a t test and data measured as statically significant at p-value<0.05.

RESULTS

Examination of control fetal cardiac tissue stained with H and E showed normal myocytes of heart tissue (Fig. 1a). Cardiac tissue of a fetus of group T1 showed Congested Blood Vessels (CBV) with numerous hemorrhagic areas (h) and numerous faintly stained nuclei (karyolysis, K) as shown in




Fig. 1(a-d): Photomicrographs of H and E stained fetal cardiac sections of the (a) Control, (b) T1 group showed Congested Blood Vessels (CBV) with numerous hemorrhagic areas (h) and numerous faintly stained nuclei (karyolysis, K), (c) T2 group showed highly Congested Blood Vessels (CBV) with scattered small pools of blood cells and deeply stained nuclei of myocytes and (d) T3 group showed congested blood vessels, numerous hemorrhagic areas (h) and karyolysis in numerous nuclei of myocytes (k), (X = 200)

Fig. 1b. Cardiac tissue of a fetus of group T2 showed highly Congested Blood Vessels (CBV) with scattered small pools of blood cells and deeply stained nuclei of myocytes (Fig. 1c). Cardiac tissue of a fetus of group T₃ showed congested blood vessels, numerous hemorrhagic areas (h) and karyolysis in numerous nuclei of myocytes (k) (Fig. 1d).

Mallory's trichrome stained sections showed thin collagen fibers in between and around the cardiac muscle fibers in control group (Fig. 2a). Highly increased collagen fibers (†) were noted in between and around the cardiac muscle fibers with numerous brightly red stained hemorrhagic areas (h) in between the muscle fibers in group T₁ (Fig. 2b). Mallory's trichrome stained sections in group T₂ showed increased collagen fibers with lots of brightly red stained hemorrhagic areas (h) in between the muscle fibers and Congested Blood Vessels (CBV) (Fig. 2c). Highly increased collagen fibers, numerous brightly stained hemorrhagic areas and congested and dilated blood vessels (h) were noted in group T₃ (Fig. 2d).

Data in Table 1 and Fig. 3a-d illustrated dense staining affinity of PAS positive materials was detected in fetal cardiac tissue of the control group (Fig. 3a), while Fig. 3b showed highly increased PAS +ve materials (†) but Some degenerated muscle fibers showed pale staining affinity in the cardiac tissue of group T₁ (MOT = 128.29). Group T₂ showed reduced staining affinity of PAS +ve materials (†) (MOT = 123.36) (Fig. 3c). Decreased staining affinity of PAS +ve materials was observed in the fetal cardiac tissue with exception of some deeply stained Blood Cells (bc) in group T₃ (MOT = 116.36) (Fig. 3d).

Table 2 and Fig. 4a-d illustrated fetal cardiac tissue of control group showed moderately stained total protein in the myocytes (MOT = 77.43) (Fig. 4a), decreased total protein in the myocytes with a slight increase in the hemorrhagic areas and the congested and dilated blood vessels were realized in cardiac tissue of T₁ group (MOT = 61.7) (Fig. 4b). Decreased total protein was demonstrated in T₂ especially in the degenerated muscle fibers but congested and dilated blood




Fig. 2(a-d): Photomicrographs of Mallory's trichrome stained fetal cardiac sections of the (a) Control group showed thin collagen fibers in between and around the cardiac muscle fibers, (b) T₁ group showed highly increased collagen fibers (†) were noted in between and around the cardiac muscle fibers with numerous brightly red stained hemorrhagic areas (h) in between the muscle fibers, (c) T₂ group showed increased collagen fibers with lots of brightly red stained hemorrhagic areas (h) in between the muscle fibers and Congested Blood Vessels (CBV) and (d) T₃ group showed highly increased collagen fibers, numerous brightly stained hemorrhagic areas and congested and dilated blood vessels (h), (X = 200)




Fig. 3(a-d): Photomicrographs of PAS +ve materials stained fetal cardiac sections of the (a) Control, (b) T1 group showed highly increased PAS +ve materials (↑) but Some degenerated muscle fibers showed pale staining affinity, (c) T2 group showed reduced staining affinity of PAS +ve materials (↓) and (d) T3 group showed decreased staining affinity of PAS +ve materials with exception of some deeply stained Blood Cells (bc), (X = 200)

Table 1: MOT values of PAS positive materials in heart of the control and treated groups

Parameters	Control	T1 group	T2 group	T3 group
Mean	96.766671	128.299998	123.366665	116.366666
S.D.	19.27556918	28.06273924	23.9762645	28.17921171
Percentage		32.58697098	27.48879725	20.25490264
t-test		0.006594135**	0.012920576**	0.077806671

*Significant at $p < 0.05$, **Highly significant at $p < 0.01$

Table 2: MOT values of total protein in heart of the control and treated groups

Parameters	Control	T1 group	T2 group	T3 group
Mean	77.433332	61.700003	68.066668	58.666667
S.D.	11.38355484	15.25377888	20.47695216	15.43005025
Percentage		-20.31854835	-12.0964238	-24.23589624
t-test		0.040214064*	0.100583206	0.000998514**

*Significant at $p < 0.05$, **Highly significant at $p < 0.01$

Table 3: MOT values of DNA content in heart of the control and treated groups

Parameters	Control	T1 group	T2 group	T3 group
Mean	44.899997	48.166666	43.233337	43.600003
S.D.	10.66806111	12.75529335	8.630445086	10.05003088
Percentage		7.275432557	-3.711937887	-2.89530977
t-test		0.25781519	0.36883244	0.420686738

*Significant at $p < 0.05$, **Highly significant at $p < 0.01$

vessels acquired deep staining affinity (MOT = 68.06) (Fig. 4c) and faintly stained degenerated muscle fibers in T3 group (MOT = 58.66) (Fig. 4d).

Table 3 illustrated the changes in DNA content in sections of fetal cardiac tissue of the control and treated groups. The MOT of DNA of the control group reached 44.89. Slightly increased staining affinity of DNA materials was observed in some nuclei of myocytes of group T₁ (MOT = 48.16). Nuclei of cardiac tissue of T₂ group and T₃ group revealed decreased staining affinity of DNA materials (MOT = 43.23 and 43.6), respectively.

DISCUSSION

Maternal fluoxetine exposure caused many histological and histochemical alternations in fetal heart of treated groups and these harmful changes increase by increasing doses of Fluoxetine. Depression during pregnancy has been lead to higher rates of deprived pregnancy outcomes such as premature delivery, preeclampsia, reduced fetal growth,




Fig. 4(a-d): Photomicrographs of mercuric bromophenol stained fetal cardiac sections of the (a) Control group showed moderately stained total protein in the myocytes, (b) T1 group showed decreased total protein in the myocytes with a slight increase in the hemorrhagic areas and the congested and dilated blood vessels (↑), (c) T2 group showed decreased total protein in the degenerated muscle fibers but congested and dilated blood vessels acquired deep staining affinity (↑) and (d) T3 group showed faintly stained degenerated muscle fibers (↑), (X = 200)

impaired fetoplacental function and neonatal problems^{27,28}. In study completed in the University Hospital of Imam Abdulrahman Bin Faisal University demonstrated that depression are common during gestation⁸. The SSRI exposure in-utero was related with increased neonatal care at delivery and differences in Apgar scores compared with normal²⁹. Use of SSRIs during gestation increases the risk of preeclampsia³⁰. The development of antenatal depression may cause by some risk factors such as biological and psychosocial factors, hormonal/reproductive past of mother, genetic setup, present stressors and life experiences³¹. By 2020 depression will become the second leading cause of worldwide disability, behind only heart disease and that depression is already the single leading cause of disability for people in midlife and for women of all ages⁷. Fluoxetine is one of the most important SSRIs and researches had focused on it because of its high selectively and negligible affinity for numerous receptors subtypes¹². Fluoxetine inhibit 5HT reuptake followed by serotonin concentration development in synaptic cleft and that removes symptoms of depression³². Fluoxetine effects on the timing of developmental stages of fetuses³³.

In the present study, fetuses maternally treated with fluoxetine (Prozac) showed numerous histopathological and histochemical changes in the fetal heart. Deleterious changes

in the fetal heart of group T₁ were observed. Congested blood vessels, numerous hemorrhagic areas and numerous faintly stained nuclei. Fetuses of group T₂ showed highly congested blood vessels with scattered small pools of blood cells and deeply stained nuclei of myocytes. Congested blood vessels, necrosis in numerous myocytes, numerous elongated hemorrhagic areas and karyolysis in numerous nuclei of myocytes were noted in-group T₂.

The SSRI exposure increase oxidative stress leading to creation of the harmful free radicals, which are damaging the fetal cardiac tissue³⁴. The expression of serotonin transporter in the fetal heart cells were inhibited by SSRIs and thereby decrease serotonin in the cells and that can disturbs the normal cardiac development³⁵. The SSRI induce neonatal adaptation problems of offspring, increase the rate of cardiac malformations, pulmonary hypertension of the newborn³⁶.

Fluoxetine and paroxetine could result in the enhancement of genetic heart defects³⁷. Fluoxetine result in right ventricular outflow tract obstruction and atrial septal defect in the heart tissue^{38,39}. Anti-depressant drug in albino rats result in swelling of glomeruli and degeneration of cells lining renal tubules in the fetal kidney tissue¹. While some other studies did not find relation between use of SSRIs and cardiac malformations^{40,18}. By histological

analysis, there is no any change in heart development of the fluoxetine exposed group¹⁵.

In the present work, increased collagen fibers were noted in the fetal heart tissue of all the treated groups, this result agree with Al-Nasser⁴¹, Nehal *et al.*² in some organs of fetuses and their mothers treated with Prozac. Myofibers were noted in the muscle fibers of Prozac group (0.06 mg Prozac/mouse/day) with variation in size, sarcolemma, amplified collagen deposition and some regions of affected empty of Golgi bodies⁴². There is no change were showed in collagen fibers of periodontal tissue⁴³.

Results illustrated changes in PAS +ve materials in fetal cardiac tissue of the control and treated groups. Highly increased PAS +ve materials was noted in fetal cardiac of fetuses of group T₁ but some degenerated muscle fibers showed pale staining affinity (MOT = 128.29 compared to the control one 96.76). Also, decreased PAS +ve materials was detected in the fetal cardiac tissue of group T₂ and T₂ with exception of some deeply stained blood (MOT was 116.36 compared to the control one 96.76).

Increased stain affinity of PAS +ve materials was founded by Eid and Al-Nasser⁴⁴ in lung tissue of pregnant rats treated with fluoxetine (0.143, 0.286 and 0.572 mg kg⁻¹ b.wt.) but they noticed diffused polysaccharides inside the blood vessels of lungs of all the treated groups.

Increased PAS +ve materials were noted in few hair follicles and hypodermal muscle fibers but decreased stain affinity was detected in the different layers of the fetal skin whose mothers received fluoxetine during pregnancy¹.

Sections from rats pretreated with fluoxetine showed strong reaction in the normal hepatocytes, faint stainability in some hepatocytes while the necrotic cells were devoid of stainable materials⁴⁵.

Increased polysaccharides in the brain of mice treated with antidepressant drugs⁴⁶, this may be dependent on adrenocortical activity⁴⁷.

In the present study, decreased total protein was demonstrated in the fetal cardiac tissue of all the treated groups (MOT values reached 61.7, 68.06, 58.66 in T₁, T₂, T₃, respectively compared with the control group 77.43). This study agreed with Song *et al.*⁴⁸, they noted decreased protein level in mice brain tissue. On the other hand, increased total proteins was noted by Kim *et al.*⁴⁹ and Eid and Al-Nasser⁴⁴ in lungs of treated pregnant rats with fluoxetine. Increased stain ability of total protein in the thickened keratin and Malpighian layers of fetal skin whose mothers received fluoxetine during pregnancy². Kim *et al.*⁴⁹ stated that fluoxetine has high affinity to bind with proteins.

Decreased stain affinity of DNA was demonstrated in then of cardiac tissue heart of fetuses of groups T₂, T₃ (MOT values reached 43.23 and 43.6 compared the control group 44.89), in spite of the presence of slightly increased staining affinity of DNA materials was observed in some nuclei of myocytes of group T₁ and MOT reached 48.16. Fadladdeen⁵⁰ noticed numerous histological and histopathological changes in many fetal organs treated maternally with Prozac. These changes include: Internal hemorrhage in the gastrointestinal tract, destructed muscle fibers and altered PAS+ve materials, total protein and DNA content.

The dissolution of DNA material in the degenerated cell due to two distinct morphological patterns of cells death have been recognized, either by necrosis or apoptosis. Apoptosis happens in both pathological and physiological conditions. It arises due to an elevation of cytosolic free calcium concentration resulting in activation of the nuclear endonuclease. Activated endonucleases produce oligonucleosome-length DNA fragments. This DNA cleavage can lead to death of cell⁵¹.

There is relation between decreased omega-3 polyunsaturated fatty acid and depression were noted by Su *et al.*⁵², so pregnant females must take enough amounts of foods rich with omega-3 for safety of mothers and their fetuses. This drug during gestation should be under strict precautions and further studies are recommended that it is essential to demonstrate the harmful effect of anti-depressant drugs on fetuses during pregnancy.

CONCLUSION

The results of the present work showed that maternal use of Prozac has been related with dystrophic changes in the fetuses and increased risk of fetal malformation. The result of this study showed that crossing of the fluoxetine from the placenta could exert adverse effects on heart development. These findings should be taken into considerate before using of Prozac during pregnancy and future researches on the placenta can lead to better understanding of the effects of Prozac use during pregnancy to improve public health outcomes. According to the result of this study, it is essential to survey the roles of anti-depressants on fetus during pregnancy.

SIGNIFICANCE STATEMENT

This study discover the harmful effect of Prozac treatment on the fetal heart tissue, that can be beneficial for prevention use of anti-depression drugs during pregnancy. This study will

help the researcher to uncover the critical areas of Prozac exposure during pregnancy that many researchers were not able to explore. Thus a new theory on injury of selective serotonin reuptake inhibitor on fetal tissues may be arrived at.

REFERENCES

1. El Ghareeb, A.E., H.A.A. El Rahman and A. Gamal, 2018. Embryo toxicity of antidepressant drug (Trazodone HCl) on albino rat fetuses. *Res. J. Pharm. Biol. Chem. Sci.*, 9: 358-371.
2. Nehal, A., A. Naja, F.A. Eid and K.A.J. Fadladden, 2011. Studies on fetal response to prozac treatment. *Egypt. J. Hosp. Med.*, 43: 145-161.
3. Viroga, S., 2018. Classification system of drug's risk during pregnancy. *J. Gynecol. Women's Health*, Vol. 8, No. 1. 10.19080/JGWH.2018.08.555726.
4. Richelson, E., 2001. Pharmacology of antidepressants. *Mayo Clin. Proc.*, 76: 511-527.
5. Bennet, H.A., A. Einarson, A. Taddio, G. Koren and T.R. Einarson, 2004. Prevalence of depression during pregnancy: Systematic review. *Obstet. Gynecol.*, 103: 698-709.
6. Nagandla, K., S. Nalliah, L.K. Yin, Z.A. Majeed and M. Ismail *et al.*, 2017. Prevalence and associated risk factors of depression, anxiety and stress in pregnancy. *Int. J. Reprod. Contracep. Obstet. Gynecol.*, 5: 2380-2388.
7. Crews, F.C., 2007. Talking back to prozac. *N. Y. Rev. Books*, 54: 215-220.
8. Alqahtani, A.H., K. Al Khedair, R. Al-Jeheiman, H.A. Al-Turki and N.H. Al Qahtani, 2018. Anxiety and depression during pregnancy in women attending clinics in a University Hospital in eastern province of Saudi Arabia: Prevalence and associated factors. *Int. J. Women's Health*, 10: 101-108.
9. Chatillon, O. and C. Even, 2010. Antepartum depression: Prevalence, diagnosis and treatment. *L'Encephale*, 36: 443-451.
10. Oberlander, T.F., W. Warburton, S. Misri, J. Aghajanian and C. Hertzman, 2006. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. *Arch. Gen. Psychiatry*, 63: 898-906.
11. Chubak, J., E.J. Bowles, M.B. Terry, A. Trentham-Dietz and D.S. Buist, 2009. Antidepressant medications and change in mammographic density in postmenopausal women. *Cancer Epidemiol. Prevent. Biomarkers*, 18: 676-679.
12. Chubak, J., D.M. Boudreau, S.J. Rulyak and M.T. Mandelson, 2011. Colorectal cancer risk in relation to antidepressant medication use. *Int. J. Cancer*, 128: 227-232.
13. Chambers, C.D., S. Hernandez-Diaz, L.J. Van Marter, M.M. Werler, C. Louik, K.L. Jones and A.A. Mitchell, 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N. Eng. J. Med.*, 354: 579-587.
14. Dias, V.G., J.S. Aguni and A.K.T. Bezzon, 2004. Síndrome de lyell por imipramina: Relato de caso. *Arq. Bras. Oftalmol.*, 67: 943-945.
15. Ghavamabadi, R.T., Z. Taghipour, M. Hassanipour, M. Khademi and M. Shariati, 2018. Effect of maternal fluoxetine exposure on lung, heart and kidney development in rat neonates. *Iran. J. Basic Med. Sci.*, 21: 417-421.
16. Wemakor, A., K. Casson, E. Garne, M. Bakker and M.C. Addor *et al.*, 2015. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: A European register-based study. *Eur. J. Epidemiol.*, 30: 1187-1198.
17. Ban, L., J.E. Gibson, J. West, L. Fiaschi and R. Sokal *et al.*, 2014. Maternal depression, antidepressant prescriptions and congenital anomaly risk in offspring: A population-based cohort study. *BJOG: Int. J. Obstet. Gynaecol.*, 121: 1471-1481.
18. Malm, H., M. Artama, M. Gissler and A. Ritvanen, 2011. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. *Obstet. Gynecol.*, 118: 111-120.
19. Jimenez-Solem, E., J.T. Andersen, M. Petersen, K. Broedbaek and J.K. Jensen *et al.*, 2012. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: A nationwide cohort study. *BMJ Open*, Vol. 2, No. 3. 10.1136/bmjopen-2012-001148.
20. Taylor, P., 1986. Handling the Reproductive Cycle and Mating. In: *Practical Teratology*, Taylor, P. (Ed.), Academic Press, London, pp: 3-9.
21. Nazari, Z., M. Nabiuni, S. Ghaffari, M. Saeidi, A. Shahriyari and M.J. Ghalipour, 2017. Gestational diabetes induces pancreatic β -cells apoptosis in adult rat offspring. *Int. J. Morphol.*, 35: 16-20.
22. Paget, G.E. and J.M. Barnes, 1964. Interspecies Dosage Conversion Scheme in Evaluation of Results and Quantitative Application in Different Species. In: *Evaluation of Drug Activities: Pharmacometric*, Laurence, D.R. and A.L. Bacharach (Eds.), Academic Press, London and USA., pp: 160-162.
23. Bancroft, J. and M. Gamble, 2002. *Theory and Practice of Histology Techniques*. 5th Edn., Churchill Livingstone, London, pp: 150-152.
24. Pearse, A.G., 1977. *Histochemistry, Theoretical and Applied*. 3rd Edn., Vol. 1, Churchill Livingstone, London.
25. Hotchkiss, R.D., 1948. A microchemical reaction resulting in the staining of polysaccharide structures in fixed tissue preparations. *Arch. Biochem.*, 16: 131-141.
26. Mazia, D., P.A. Brewer and M. Alfert, 1953. The cytochemical staining and measurement of protein with mercuric bromphenol blue. *Biol. Bull.*, 104: 57-67.

27. Wisner, K.L., D.K.Y. Sit, B.H. Hanusa, E.L. Moses-Kolko and D.L. Bogen *et al.*, 2009. Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. *Am. J. Psychiatry*, 166: 557-566.
28. El Marroun, H., V.W. Jaddoe, J.J. Hudziak, S.J. Roza and E.A. Steegers *et al.*, 2012. Maternal use of selective serotonin reuptake inhibitors, fetal growth and risk of adverse birth outcomes. *Arch. Gen. Psychiatry*, 69: 706-714.
29. Hogue, A.N., M.E. Temple-Cooper, M. Lagzdins, S. Worley, J. Scwersenski, R. Floyd and F. Saker, 2017. Effects of in-utero exposure to selective serotonin reuptake inhibitors and venlafaxine on term and preterm infants. *J. Neonatal-Perinatal Med.*, 10: 371-380.
30. Olivier, J.D.A., H. Akerud, H. Kaihola, J.L. Pawluski, A. Skalkidou, U. Hogberg and I. Sundstrom-Poromaa, 2013. The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring. *Front. Cell. Neurosci.*, Vol. 7. 10.3389/fncel.2013.00073.
31. Miller, L.J. and E.M. LaRusso, 2011. Preventing postpartum depression. *Psychiat. Clin.*, 34: 53-65.
32. Murphy, D.L., A. Lerner, G. Rudnick and K.P. Lesch, 2004. Serotonin transporter: Gene, genetic disorders and pharmacogenetics. *Mol. Interv.*, 4: 109-123.
33. Kaihola, H., F.G. Yaldir, J. Hreinsson, K. Hornaeus and J. Bergquist *et al.*, 2016. Effects of fluoxetine on human embryo development. *Front. Cell. Neurosci.*, Vol. 10. 10.3389/fncel.2016.00160.
34. Nembhard, W.N., X. Tang, Z. Hu, S. MacLeod, Z. Stowe and D. Webber, 2017. Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors and risk of congenital heart defects in offspring: Population based study. *BMJ.*, Vol. 356. 10.1136/bmj.j832.
35. Velasquez, J.C., N. Goeden and A. Bonnin, 2013. Placental serotonin: Implications for the developmental effects of SSRIs and maternal depression. *Front. Cell. Neurosci.*, Vol. 7. 10.3389/fncel.2013.00047.
36. Ornoy, A. and G. Koren, 2018. Selective serotonin reuptake inhibitor use in pregnant women; pharmacogenetics, drug-drug interactions and adverse effects. *Expert Opin. Drug Metab. Toxicol.*, 14: 247-259.
37. Knudsen, T.M., A.V. Hansen, E. Garne and A.M.N. Andersen, 2014. Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy-an epidemiological study using validated EUROCAT data. *BMC Pregnancy Childbirth*, Vol. 14, No. 1. 10.1186/1471-2393-14-333.
38. Furu, K., H. Kieler, B. Haglund, A. Engeland and R. Selmer *et al.*, 2015. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: Population based cohort study and sibling design. *BMJ.*, Vol. 350. 10.1136/bmj.h1798.
39. Daud, A., J. Bergman, W. Kerstjens-Frederikse, H. Groen and B. Wilffert, 2016. The risk of congenital heart anomalies following prenatal exposure to serotonin reuptake inhibitors-Is pharmacogenetics the key? *Int. J. Mol. Sci.*, Vol. 17, No. 8. 10.3390/ijms17081333.
40. Reis, M. and B. Kallen, 2010. Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. *Psychol. Med.*, 40: 1723-1733.
41. Al-Nasser, F., 2008. Effect of Prozac (fluoxetine) on some tissues of the pregnant rats and their fetuses. M.Sc. Thesis, College of Science, King Faisal University, Dammam, KSA.
42. Ali, A.M. and F.A. Hakami, 2012. Comparative studies on the effect of Prozac drug and Barely grains on the skeletal muscles of mice: Behavioral and histological studies. *J. Applied Pharm. Sci.*, 2: 45-51.
43. Regueira, L.S., P.G.C.L. de Marcelos, I.M. Santiago-Jaegger, D.E.D.C. Perez, J.E. Neto and L. Baratella-Evencio, 2017. Fluoxetine effects on periodontogenesis: Histomorphometrical and immunohistochemical analyses in rats. *J. Applied Oral Sci.*, 25: 159-167.
44. Eid, F. and F. Al-Nasser, 2008. Histological and histochemical changes in lung of pregnant rats treated with an antidepressant drug (Prozac). *J. Biol. Pharm. Sci.*, 6: 99-114.
45. Abdel Salam, O.M.E., N.A. Mohammed, A.A. Sleem and A.R. Farrag, 2013. The effect of antidepressant drugs on thioacetamide-induced oxidative stress. *Eur. Rev. Med. Pharmacol. Sci.*, 17: 735-744.
46. Hutchins, D.A. and K.J. Rogers, 1970. Physiological and drug induced changes in the glycogen content of mouse brain. *Br. J. Pharmacol.*, 39: 9-25.
47. Mills, J.N., 1966. Human circadian rhythms. *Physiol. Rev.*, 46: 128-171.
48. Song, D., K. Ma, A. Verkhatsky and L. Peng, 2018. L-dopa and fluoxetine upregulate astroglial 5-HT_{2B} receptors and ameliorate depression in Parkinson's disease mice. *Neuroglia*, 1: 48-62.
49. Kim, J., K.W. Riggs and D.W. Rurak, 2004. Stereoselective pharmacokinetics of fluoxetine and norfluoxetine enantiomers in pregnant sheep. *Drug Metab. Dispos.*, 32: 212-221.
50. Fadladdeen, K.A., 2011. Studies on fetal response to Prozac treatment. Ph.D. Thesis, Zoology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.
51. Fawthrop, J.F., A. Boobis and E. Davies, 1979. Mechanism of death. *Lancet*, 24: 412-413.
52. Su, K.P., S.Y. Huang, T.H. Chiu, K.C. Huang, C.L. Huang, H.C. Chang and C.M. Pariante, 2008. Omega-3 fatty acids for major depressive disorder during pregnancy: Results from a randomized, double-blind, placebo-controlled trial. *J. Clin. Psychiatry*, 69: 644-651.